Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aloliv
- Development stage
- Unknown
- Lead developer
- Bennet Pharmaceuticals
- Modality
- Classical Binding Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Aloliv** is an oral fixed-dose hepatoprotective product marketed by Mypher Pharmaceuticals. It combines **silymarin**, a milk-thistle-derived flavonolignan extract, with **lecithin**, a phospholipid preparation. The manufacturer lists Aloliv oral suspension as containing silymarin 35 mg plus lecithin 125 mg per 5 mL and identifies alcoholic liver disease, infective hepatitis, liver cirrhosis, and chronic active hepatitis as indications. The same brand is also marketed as a softgel capsule containing silymarin 140 mg plus lecithin 525 mg. ([mypherpharma.com](https://mypherpharma.com/aloliv-200ml.html))
- Brand names
- Aloliv
- Other names
- Aloliv CapAloliv CapsuleAloliv Softgel CapsuleAloliv SuspensionAloliv Syrup
Beyond the preview
Go deeper on Aloliv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aloliv.